

40 (6)

J Rheumatol 2013;40:749-1031  
<http://www.jrheum.org/content/40/6.citation>

1. Sign up for TOCs and other alerts  
<http://www.jrheum.org/alerts>
2. Information on Subscriptions  
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints  
[http://jrheum.com/reprints\\_permissions](http://jrheum.com/reprints_permissions)

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

# The Journal of Rheumatology

VOLUME 40: NO. 6

jrheum.org

JUNE 2013

## Editorials

- Osteonecrosis of the Jaw and Rheumatoid Arthritis. Is It the Disease or the Drugs?** *R. Landesberg, P. Taxel* . . . . 749
- Prevention of Rheumatoid Arthritis: The Very First Steps**  
*A. Masetto, M-C. Beaulieu, G. Boire* . . . . . 752
- The Real World of Gout** *R. Conway* . . . . . 755
- Jeopardizing Validity by Mismeasurement of Quality of Life**  
*J. Richardson, N.A. Day* . . . . . 758

## Review

- Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome**  
*R. Strippoli, I. Caiello, F. De Benedetti* . . . . . 761

## Articles

- Longterm Safety and Efficacy of Tocilizumab in Patients with RA: A Cumulative Analysis of Up to 4.6 Years of Exposure**  
*M.C. Genovese, A. Rubbert-Roth, J.S. Smolen, et al* . . . . 768
- Osteonecrosis of the Jaw and Nonmalignant Disease: Is There an Association with RA?**  
*G. Lescaille, A.E. Coudert, V. Baaroun, et al* . . . . . 781
- Safety of Abatacept Administered Intravenously in Treatment of RA: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program**  
*M.E. Weinblatt, L.W. Moreland, R. Westhovens, et al* . . . . 787
- Association of Polymorphisms Modulating LDL Cholesterol with Susceptibility, Severity, and Progression of RA**  
*Y-J. Park, S-A. Yoo, S. Choi, et al* . . . . . 798
- CV Events Are Not Associated with MTHFR Polymorphisms, But Are Associated with MTX Use and Traditional Risk Factors in US Veterans with RA**  
*L.A. Davis, G.W. Cannon, L.F. Pointer, et al* . . . . . 809
- First-degree Relatives of Patients with RA Exhibit High Prevalence of Joint Symptoms**  
*I. Smolik, D.B. Robinson, C.N. Bernstein, H.S. El-Gabalawy* . . . . . 818

- HDL Profiling Changes in Patients with RA Treated with TNF Inhibitors: A Cohort Study**  
*A. Jamnitski, J.H. Levels, I.A. van den Oever, M.T. Nurmohamed* . . . . . 825
- The Early Protective Effect of HCQ on the Risk of Cumulative Damage in Patients with SLE**  
*P.S. Akhavan, J. Su, W. Lou, D.D. Gladman, M. Urowitz, P.R. Fortin* . . . . . 831
- Variable Association of Reactive Intermediate Genes with SLE in Populations with Different African Ancestry**  
*P.S. Ramos, J.C. Oates, D.L. Kamen, et al* . . . . . 842
- Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in SSC**  
*X.J. Zhang, A. Bonner, M. Hudson, the Canadian Scleroderma Research Group, M. Baron, J. Pope* . . . . . 850
- Comparison of EQ-5D and SF-6D Utility Scores in Multiethnic Asian Patients with PsA: A Cross-sectional Study**  
*Y-Y. Leung, M-E. Png, H-L. Wee, J. Thumboo* . . . . . 859
- Soluble Biomarkers Associated with Response to Treatment with TNF Inhibitors in PsA**  
*V. Chandran, H. Shen, R.A. Pollock, et al* . . . . . 866
- Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population**  
*K. Pui, P.J. Gow, N. Dalbeth* . . . . . 872
- Expression of PPAR  $\alpha$ ,  $\beta$ ,  $\gamma$ , and H- and L-Prostaglandin D Synthase During OA in the Spontaneous Hartley Guinea Pig and Experimental Dog Models**  
*S-S. Nebbaki, F.E. El Mansouri, H. Afif, et al* . . . . . 877
- Identifying Phenotypes of Knee OA by Separate Quantitative Radiographic Features May Improve Patient Selection for More Targeted Treatment**  
*M.B. Kinds, A.C.A. Marijnissen, M.A. Viergever, P.J. Emans, F.P.J.G. Lafeber, P.M.J. Welsing* . . . . . 891
- Kynurenic Acid in Synovial Fluid and Serum of Patients with RA, SpA, and OA**  
*J. Parada-Turska, W. Zgrajka, M. Majdan* . . . . . 903
- Statin Use in Giant Cell Arteritis: A Retrospective Study**  
*J. Schmidt, T.A. Kermani, F. Muratore, C.S. Crowson, E.L. Matteson, K.J. Warrington* . . . . . 910

 Free online via JRheum Full Release option

Contents continued opposite inside back cover . . .

---

**Antibiotics for Treatment of ReA: A Systematic Review and Metaanalysis** *C.E. Barber, J. Kim, R.D. Inman, J.M. Esdaile, M.T. James* ..... 916

## Pediatric

**Childhood-onset Eosinophilic Granulomatosis with Polyangiitis (formerly Churg-Strauss Syndrome): A Contemporary Single-center Cohort**  
*S. Gendelman, A. Zeft, S.J. Spalding* ..... 929

**Race, Ethnicity, and Disease Outcomes in JIA: A Cross-sectional Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry**  
*S. Ringold, T. Beukelman, P.A. Nigrovic, Y. Kimura, for the Carra Registry Investigators* ..... 936

**Etanercept Improves Lipid Profile and Oxidative Stress Measures in Patients with JIA**  
*S. De Sanctis, M.L. Marcovecchio, S. Gaspari, et al.* ..... 943

## Images in Rheumatology

**Infectious Tenosynovitis in a Patient with Dermatopolymyositis and Vasculitis**  
*C. Canella, M. Pacheco, F. Costa, E. Marchiori* ..... 949

**Canadian Rheumatology Association Meeting**  
**Ottawa, Ontario, Canada**  
**February 13–16, 2013**

Abstracts ..... 950

## Letters

**CCL18 Activates Fibroblast-like Synoviocytes in Patients with RA**  
*A. Takayasu, Y. Miyabe, W. Yokoyama, et al.* ..... 1026

**Cyclophosphamide Exposure in Pediatric SLE Is Associated with Reduced Serum Anti-Müllerian Hormone Levels**  
*J. Isgro, S.K. Nurudeen, L.F. Imundo, M.V. Sauer, N.C. Douglas* ..... 1029

Meetings in Rheumatology ..... x